What it is:A catalog of the ways drugs can make lungs sick, organized by where in the respiratory system the damage happens instead of by drug class. That organization matters more than it sounds like it should, because a single drug (amiodarone, nitrofurantoin) can cause three or four completely different-looking pictures depending on how long someone has been on it and how their immune system responds.
The core problem:New cough, dyspnea, or an infiltrate on chest imaging has an enormous differential: pneumonia, heart failure, PE, asthma exacerbation, ILD from a rheum disease, and idiopathic fibrosis all live in the same symptom space as a drug reaction. If you don't systematically ask "what is this patient taking that's a known lung offender," you'll chase infection or cardiac causes while the actual culprit sits in the med list.
What you do about it:Sort the presentation into one of three buckets (tissue damage to the interstitium/alveoli, tissue damage to the pleura, or a reflex/mechanical problem with no actual tissue injury), cross-check the patient's drug list against the classic culprits for that bucket, and stop the drug while you build the case.
Ask two questions for every case. Where is the drug hitting?The interstitium/alveoli (the largest bucket by far, six distinct patterns), the pleura (two patterns, one nonspecific and one lupus-like), or nowhere structurally at all, just a reflex, a vascular change, or a ventilatory drive problem. What's the timeline?Minutes to hours points toward a true hypersensitivity reaction, days to weeks points toward an acute toxic or immune process, and months to years points toward cumulative, dose-related fibrosis. Getting the bucket and the timeline right narrows a huge differential down to a short list fast.
Drugs (or their reactive metabolites) reach the lung through the pulmonary circulation and can injure it by three fundamentally different mechanisms, and which one is in play determines both the picture you see and whether corticosteroids will actually help.
Direct or immune-mediated injury to the alveolar-capillary unitis the biggest category. Oxidative damage (bleomycin), direct cytotoxicity (many chemo agents), phospholipid accumulation (amiodarone), or a cell-mediated immune response against the drug or a drug-altered lung protein all converge on the same structures: the alveolar epithelium, the capillary endothelium, and the interstitium between them. Depending on how acute and how severe the insult is, you get anything from edema to fibrosis to frank hemorrhage.
Pleural injuryis a smaller, separate compartment problem. Some drugs cause a nonspecific inflammatory pleural reaction. A short list of drugs (procainamide chief among them) actually trigger a lupus-like autoimmune process, and the pleura is one of the first places that autoimmune activity shows up.
Functional reactions with no structural injuryare the odd bucket out and the one people forget exists. Beta-blockers causing bronchospasm, ACE inhibitors causing cough, opioids blunting the ventilatory drive or stiffening the chest wall: none of these are damaging lung tissue. They're altering airway smooth muscle tone, a neural reflex arc, vascular tone, or the mechanics of breathing itself.
This is the single most testable idea in the whole appendix. Corticosteroids show up in the management column for almost every interstitial, alveolar, and pleural pattern because those are immune or inflammatory processes. Corticosteroids do nothingfor the functional reactions: naloxone reverses opioid apnea, stopping the drug and supportive ventilation manage chest wall rigidity, and anticoagulation treats a drug-associated PE. If a management plan reaches for steroids to treat opioid-induced apnea, that's the tell that the bucket was misidentified.
Six distinct patterns live here, and they overlap enough in presentation (cough, dyspnea, an abnormal CXR) that the diagnostic clues in the middle column are what actually separate them.
| Pattern | Presentation | Diagnostic clues | Classic culprits | Management |
|---|---|---|---|---|
| Interstitial pneumonitis / fibrosis | Acute or chronic; dyspnea, cough, clubbing, crackles | Bilateral opacities + reduced lung volumes on CXR; "honeycombing" on CT; restrictive or normal PFTs; ESR climbs specifically with amiodarone | Amiodarone, bleomycin, gemcitabine, carmustine, cyclophosphamide, taxanes, EGFR inhibitors, dasatinib, mTOR inhibitors, busulfan, sulfasalazine, methotrexate, leflunomide, phenytoin, nitrofurantoin, daptomycin | Stop or reduce dose, corticosteroids, O2 |
| Organizing pneumonia | Nonproductive cough, dyspnea, bilateral crackles; fever less commonly | Bilateral patchy infiltrates on CXR; eosinophilia rare | Amiodarone, bleomycin, minocycline, nitrofurantoin, gold, sulfasalazine, interferon alfa, carbamazepine, L-tryptophan, cocaine | Stop drug, corticosteroids, O2 |
| Eosinophilic pneumonia | Acute or chronic; dry cough, dyspnea, chest pain, fever | Bilateral reticular/ground-glass opacities on CT; acute = peripheral neutrophils + high BAL eosinophils; chronic = peripheral eosinophils + elevated IgE, CRP, ESR | Daptomycin, mesalamine, sulfasalazine, minocycline | Stop drug, corticosteroids, omalizumab, O2; acute cases often need mechanical ventilation |
| Hypersensitivity pneumonitis | Usually immediate; urticaria, angioedema, rhinitis, conjunctivitis, dyspnea, bronchospasm | Clinical diagnosis, made from the presentation itself | NSAIDs (dose-dependent), methotrexate, nitrofurantoin | Stop drug, corticosteroids, antihistamines, O2 |
| Noncardiac pulmonary edema | Dyspnea, chest discomfort, tachypnea, hypoxemia | Interstitial and alveolar infiltrates; labs and PFTs are not diagnostically useful here | Cytarabine, gemcitabine, immune globulins, interleukins, methotrexate, mitomycin, muronomab-CD3, pentostatin, tretinoin, vinca alkaloids, TCAs, aspirin (dose-dependent), methadone, morphine, heroin, oxytocin, protamine, infliximab, GM-CSF, amiodarone, nitrofurantoin, talc, cocaine | Stop drug, diuretics, O2, mechanical ventilation; corticosteroid benefit is uncertain |
| Diffuse alveolar damage | Typically acute, can be subacute; hemoptysis, cough, dyspnea, acute respiratory failure | New or unexplained infiltrates on CXR; dropping hematocrit; hemorrhagic BAL | Chemotherapy agents broadly, all-trans-retinoic acid, propylthiouracil, penicillin, sulfasalazine, hydralazine, leukotriene antagonists, mitomycin, amiodarone, nitrofurantoin, crack cocaine, thrombolytics, anticoagulants, antiplatelets, dextran 70 | Stop drug, reverse coagulation, corticosteroids (for chemo-induced cases), O2 |
Both sound like allergic reactions and both can be triggered by the same drug class (NSAIDs, minocycline-family agents), which is exactly why they get mixed up. Hypersensitivity pneumonitis hits immediatelyand looks like a true allergic reaction: urticaria, angioedema, bronchospasm, on top of dyspnea. Eosinophilic pneumonia can be acute or chronic, is a slower-building process centered on eosinophil-driven alveolar inflammation, and is confirmed with BAL or peripheral eosinophilia and elevated IgE, not by the skin and airway findings that define hypersensitivity pneumonitis.
A patient on an anticoagulant, antiplatelet, or thrombolytic who develops hemoptysis with new infiltrates and a falling hematocrit needs coagulation reversed immediately, not a routine pulmonology referral. This combination is a medical emergency, and the culprit drug list overlaps heavily with agents you'd otherwise be reluctant to stop (anticoagulants in a patient with another indication for them), which is exactly why recognizing the pattern fast matters.
Two patterns here, and they present almost identically (pleuritic chest pain plus an effusion). The pleural fluid analysis is what actually tells them apart.
| Pattern | Presentation | Diagnostic clues | Classic culprits | Management |
|---|---|---|---|---|
| Nonlupus-related pleural effusion | Pleuritic chest pain, pleural effusion | Pleural fluid eosinophilia (nonspecific finding); elevated peripheral eosinophils | Sclerotherapy agents (most common cause), amiodarone, minoxidil, methysergide, bromocriptine, bleomycin, mitomycin, procarbazine, methotrexate, cyclophosphamide, dasatinib | Stop drug, corticosteroids, O2 |
| Lupus-related pleural effusion | Pleuritic chest pain, pleural effusion | Mimics idiopathic lupus; pleural fluid is exudative, ANA titer runs higher in the pleural fluid than in serum, lupus erythematosus cells may be seen | Procainamide (most common), hydralazine, chlorpromazine, isoniazid, D-penicillamine, methyldopa, quinidine | Stop drug, O2 (typically resolves on its own once the drug is withdrawn) |
If a test question pairs "drug-induced lupus" with a specific drug, procainamide is the answer more often than anything else on that list, followed by hydralazine. Both are older antiarrhythmic/antihypertensive agents, and both are worth knowing cold precisely because they're still prescribed in situations (refractory arrhythmias, resistant hypertension) where this diagnosis needs to stay on your radar.
Don't try to distinguish these two by history and exam alone, since pleuritic pain and an effusion look the same either way. Send the pleural fluid for eosinophil count (nonlupus) and compare ANA titer in fluid versus serum (lupus-related). A pleural ANA that's higher than the simultaneous serum ANA is the specific tell for the lupus-related pattern.
Nothing in this bucket is actually destroying lung tissue. These are reflex, vascular, coagulation, or ventilatory-mechanics problems, which is exactly why the management column looks so different from everything above.
| Pattern | Presentation | Diagnostic clues | Classic culprits | Management |
|---|---|---|---|---|
| Bronchospasm | Wheezing | Clinical diagnosis, made from the presentation | Acetaminophen, aspirin, NSAIDs, beta-blockers, iodinated radiocontrast dye | Stop drug, corticosteroids, O2 |
| Cough | Persistent dry cough or a "tickle" in the throat; can start anywhere from hours to months after starting the drug | Clinical diagnosis | ACE inhibitors, calcium channel blockers, fentanyl, latanoprost ophthalmic | Stop drug |
| Pulmonary arterial hypertension | Dyspnea | mPAP ≥25 mm Hg at rest, confirmed on right heart catheterization | Anorectic agents, amphetamines, dasatinib, SSRIs (fetal risk if the mother is taking one) | Stop drug, pulmonary vasodilators |
| Thromboembolic disorders | Dyspnea | Pulmonary embolism confirmed on chest CT | Bleomycin, cyclophosphamide, other alkylating/alkylating-like agents, mitomycin, high-dose combined oral contraceptives, immune checkpoint inhibitors | Stop drug, anticoagulation, thrombolysis, O2 |
| Apnea | Hypoventilation | Clinical diagnosis | Opioids, neuromuscular blockers | Dose reduction or discontinuation; naloxone for opioid-induced apnea |
| Chest wall rigidity | Decreased compliance of the chest wall, respiratory muscles, or laryngeal structures | Clinical diagnosis, usually recognized during or after IV administration | Synthetic opioids (fentanyl, remifentanil, methadone), also morphine | Dose reduction or discontinuation |
This is a distinct entity from ordinary opioid-induced apnea and it's an anesthesia/procedural sedation emergency. High-dose or rapid IV fentanyl (and other synthetic opioids) can stiffen the chest wall and larynx to the point that you cannot ventilate the patient with a bag-mask, even though naloxone is on board. Recognize it fast, because the fix is often neuromuscular blockade to allow ventilation, not just more naloxone.
ACE inhibitors block the breakdown of bradykinin and substance P in addition to blocking angiotensin conversion, and the buildup of those peptides in the airway is what triggers the cough. That's why switching to an ARB, which doesn't touch bradykinin metabolism, reliably resolves an ACE inhibitor cough instead of just trading one culprit for a related one.
Once you've matched the presentation to a pattern, the next question is the same one every drug-induced disease workup asks: did the drug actually cause this? The appendix frames that causality assessment as three time-anchored questions, the same underlying logic as a formal tool like RUCAM for liver injury, just condensed.
| Timepoint | What you're establishing |
|---|---|
| History | Is there known or suspected exposure to a drug already reported to cause drug-induced pulmonary disease? |
| Current | Do the clinical and histopathologic findings correlate with previous reports of this drug causing this pattern, and can other causes (infection, heart failure, primary ILD, PE from a non-drug cause) be ruled out? |
| Future | Do clinical manifestations improve after the drug is withdrawn (positive dechallenge), and do they recur if the patient is re-exposed (positive rechallenge)? |
If you've worked through the liver injury appendix, this triad should look familiar: exposure history, a current picture that fits and has ruled out mimics, and a future trajectory (dechallenge, rechallenge) that confirms the link. Drug-induced pulmonary disease doesn't have its own widely used numeric score the way liver injury has RUCAM, so this three-part framework is the practical substitute you actually apply at the bedside.
A handful of drugs show up across three, four, or five different patterns in the tables above. Knowing which ones those are, and why, is worth more than memorizing any single row.
| Drug | Patterns it's linked to | Why it shows up everywhere |
|---|---|---|
| Amiodarone | Interstitial pneumonitis/fibrosis, organizing pneumonia, noncardiac pulmonary edema, diffuse alveolar damage, nonlupus pleural effusion | Iodine-rich, huge volume of distribution, and a half-life measured in weeks; toxicity can show up (or keep worsening) long after a dose reduction, and it causes direct cytotoxic injury on top of phospholipid accumulation in lung tissue |
| Nitrofurantoin | Interstitial pneumonitis/fibrosis, organizing pneumonia, hypersensitivity pneumonitis, noncardiac pulmonary edema, diffuse alveolar damage | Causes both an acute hypersensitivity-type reaction and a separate chronic, duration-dependent fibrotic process; the chronic pattern is the one to watch for with long-term UTI prophylaxis |
| Bleomycin | Interstitial pneumonitis/fibrosis, organizing pneumonia, nonlupus pleural effusion, thromboembolic disease | Oxygen free radical-mediated direct lung injury that's cumulative-dose dependent, which is also why supplemental oxygen is given cautiously in anyone with a bleomycin exposure history |
| Methotrexate | Interstitial pneumonitis/fibrosis, hypersensitivity pneumonitis, noncardiac pulmonary edema | Hypersensitivity-type mechanism that isn't cleanly dose related, so it can appear even at standard low weekly rheumatologic dosing |
| Sulfasalazine | Interstitial pneumonitis/fibrosis, organizing pneumonia, eosinophilic pneumonia, diffuse alveolar damage | Immune-mediated reactions tied to the sulfa moiety, spanning an unusually broad range of patterns for one drug |
| Mitomycin | Noncardiac pulmonary edema, diffuse alveolar damage, nonlupus pleural effusion | Direct toxicity to alveolar and pleural endothelium |
| Cyclophosphamide | Interstitial pneumonitis/fibrosis, nonlupus pleural effusion, thromboembolic disease | Two distinct fibrotic timelines described, an early-onset pattern that can improve after stopping the drug and a late-onset pattern that tends to progress regardless |
Each one appears in five of the eight interstitial/alveolar and pleural patterns. If a case stem mentions either drug alongside any new respiratory symptom, drug-induced pulmonary disease belongs near the top of your differential, not as an afterthought.
Several repeat offenders (amiodarone for a dangerous arrhythmia, methotrexate for severe rheumatoid disease, bleomycin as part of a curative chemo regimen) are treating something serious in their own right. Stopping the lung-toxic drug is still the first move once a pattern is identified, but it's worth explicitly weighing that decision with the prescriber managing the original indication rather than treating it as automatic.
| Parameter | When | Watching for |
|---|---|---|
| Chest X-ray / chest CT | Baseline before starting a known pulmonary-toxic agent (amiodarone, bleomycin, methotrexate), then at intervals or with any new respiratory symptom | New or worsening infiltrates, honeycombing, or a new effusion |
| PFTs, especially DLCO | Baseline before agents like bleomycin and amiodarone, then periodically through therapy | A declining DLCO, which often shows up before symptoms or CXR changes do |
| Pulse oximetry / ABG | Any patient on a culprit drug who develops new dyspnea | Hypoxemia and its severity |
| CBC with differential | Whenever an eosinophilic or hemorrhagic pattern is suspected | Peripheral eosinophilia; a dropping hematocrit in suspected diffuse alveolar hemorrhage |
| ESR, CRP, IgE | Working up eosinophilic pneumonia or a chronic interstitial pattern | Trending inflammatory markers that support an active immune process |
| ANA (paired serum and pleural fluid) | Pleuritic symptoms in a patient on a lupus-inducing drug | Pleural fluid ANA titer higher than serum, supporting a lupus-related effusion |